General Comments / Chat, page-3244

Just my two cents in relation to some of the points raised regarding medical professionals in the Chart and Share Price Action discussion. I think that an RAC investor with a moderate understanding of the role of FTO in cancer and disease, dose and dosing regimen required for pharmacological inhibition of FTO, and evidence supporting FTO inhibition in clinical trials is likely more knowlegdable than most other medical professionals not engaged in research of this specific field. While this may be the case, I can only really speak from my own perspective and as such, say the following sincerely to simply illustrate a point. I have probably devoted over 1000-hours studying this space, which has largely been led by personal interest (maybe a pinch of obsession) as well as things like emailing credentialed scientists like Professor He and Jianjun Chen. The content discussed in this forum spans from 40 years ago to days or even hours after publication, which means that a credible alternative view would first need to devote a significant amount of time and be explicitly up to date with new developments in the FTO, mRNA methylation/demethylation, and/or m6A modification space. People who label themselves as oncologists or research scientists commenting on Bisantrene, referring to it as an anthracycline or cardio friendly chemotherapeutic, highlight that they no idea what they are talking about. I admit that I am by no means more intelligent than these other people or that I contain some kind of esoteric knowledge, rather that for me to take a contrary viewpoint seriously, regardless of their profession, a person would have to generate an extremely strong, evidence-based case (which I would value). I understand why medical professionals may be skeptical of bisantrene, since as a dietitian and PT, I am skeptical of the diet or workout program that is apparently the next big thing. Personally, I do not read too much into whether people want to or do not want to invest into this company, because I trust my own judgement which has been formed through hours of hard work. I encourage anyone who questions the legitimacy of Bisantrene as an FTO-directed anti-cancer agent to present a case where it is not - I will welcome it graciously and respond in detail.